Invesco India Pharma and Healthcare Fund Direct Growth

Invesco India Pharma and Healthcare Fund Direct Growth: NAV ₹10.65, expense ratio 1.91%. Returns vs index, rolling returns, holdings, Direct vs Regular and peers, by a SEBI Registered Research Analyst.

Key facts

NAV
₹10.6500 (19 Nov 2026)
Expense ratio
1.91%
Exit load
Exit Load^: For each purchase of units through Lumpsum / switch-in / Systematic Investment Plan (SIP), Systematic Transfer Plan (STP) and IDCW Transfer Plan, exit load will be as follows: • if units are redeemed/switched out on or before 3 months from the date of allotment: 0.50% • if units are redeemed/switched-out after 3 months: Nil • Switch between the Plans under the Scheme: Nil ^Exit Load charged, if any, will be credited back to the scheme, net of Goods and Services Tax
Minimum investment
Rs. 1,000/-
Category
Sectoral Fund
Benchmark
BSE Healthcare TRI
Riskometer
Very High Risk
Fund manager
Mr. Aditya Khemani
Launch date
18 Aug 2026

Frequently asked questions

What is the NAV of Invesco India Pharma and Healthcare Fund Direct Growth today?

The NAV of Invesco India Pharma and Healthcare Fund Direct Growth is ₹10.6500 as of 19 Nov 2026.

What is the expense ratio of Invesco India Pharma and Healthcare Fund Direct Growth?

The expense ratio (TER) is 1.91% a year.

Is there an exit load on Invesco India Pharma and Healthcare Fund Direct Growth?

Exit load: Exit Load^: For each purchase of units through Lumpsum / switch-in / Systematic Investment Plan (SIP), Systematic Transfer Plan (STP) and IDCW Transfer Plan, exit load will be as follows: • if units are redeemed/switched out on or before 3 months from the date of allotment: 0.50% • if units are redeemed/switched-out after 3 months: Nil • Switch between the Plans under the Scheme: Nil ^Exit Load charged, if any, will be credited back to the scheme, net of Goods and Services Tax.

How risky is Invesco India Pharma and Healthcare Fund Direct Growth?

Its SEBI riskometer is "Very High Risk" and it is in the Sectoral Fund category.

What is the benchmark of Invesco India Pharma and Healthcare Fund Direct Growth?

The benchmark is BSE Healthcare TRI. This page compares the fund with its benchmark's total-return index (TRI).

Research by iNVESTT, a SEBI Registered Research Analyst (INH000010858). Data from AMFI. Mutual fund investments are subject to market risks; past performance does not guarantee future returns.

Mutual fund research · Fund screener · Compare this fund · SIP calculator · Personal advisory